HALEON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 320.8 GBX | -0.09% |
|
-2.14% | -0.26% |
| 06-05 | Haleon: share price rises, Berenberg initiates buy decision | CF |
| 06-05 | Transcript : Haleon plc Presents at 21st Annual dbAccess Global Consumer Conference 2024, Jun-05-2024 04:30 PM |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 11.45B 14.65B 1,145B | Sales 2025 * | 11.94B 15.28B 1,194B | Capitalization | 29.3B 37.48B 2,930B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.49B 1.91B 149B | Net income 2025 * | 1.71B 2.19B 171B | EV / Sales 2024 * | 3.24 x |
| Net Debt 2024 * | 7.82B 10B 782B | Net Debt 2025 * | 7.06B 9.03B 706B | EV / Sales 2025 * | 3.04 x |
| P/E ratio 2024 * |
19.9
x | P/E ratio 2025 * |
17.2
x | Employees | 25,408 |
| Yield 2024 * |
1.93% | Yield 2025 * |
2.22% | Free-Float | 81.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haleon plc
More press releases
More news
| 1 day | -0.09% | ||
| 1 week | -2.14% | ||
| Current month | -1.32% | ||
| 1 month | -2.14% | ||
| 3 months | -3.26% | ||
| 6 months | -2.05% | ||
| Current year | -0.26% |
1 week
319.90
333.23
1 month
319.90371.20
Current year
308.37371.20
1 year
306.80371.20
3 years
241.17371.20
5 years
241.17371.20
10 years
241.17371.20
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McNamara
CEO | Chief Executive Officer | 57 | 21/07/21 |
Tobias Hestler
DFI | Director of Finance/CFO | 52 | 30/11/21 |
Franck Riot
CTO | Chief Tech/Sci/R&D Officer | - | 15/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bryan Supran
BRD | Director/Board Member | - | 17/07/22 |
Dame Cox
BRD | Director/Board Member | 64 | 17/07/22 |
Tracy Clarke
BRD | Director/Board Member | 57 | 17/07/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 142 M€ | +14.39% | - | |
| 0.99% | 11 M€ | +0.83% | - | |
| 0.94% | 4 M€ | +18.30% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/24 | 320.8 | -0.09% | 36,720,090 |
| 11/06/24 | 321.1 | -0.68% | 18,583,510 |
| 10/06/24 | 323.3 | -2.12% | 14,788,230 |
| 07/06/24 | 330.3 | -0.30% | 10,097,480 |
| 06/06/24 | 331.3 | +1.07% | 10,436,120 |
Delayed Quote London S.E., June 12, 2024 at 04:35 pm
More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.208
GBP
Average target price
3.646
GBP
Spread / Average Target
+13.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.26% | 37.31B | |
| +48.79% | 780B | |
| +41.76% | 627B | |
| +19.43% | 334B | |
| +7.18% | 296B | |
| +17.60% | 244B | |
| -0.41% | 217B | |
| +11.54% | 214B | |
| +4.53% | 161B | |
| -3.92% | 159B |
- Stock Market
- Equities
- HLN Stock